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value-based pricing, which reflects disease burden, therapeutic innovation, and 
social values, is suggested. This study attempts to measure the importance of cost-
effectiveness and other values for a new anticancer drug. Methods: Through 
literature reviews and experts’ advices, eight health insurance benefit criteria 
were selected: disease severity, size of population affected by disease, pediatric 
medicine, alternative drugs, innovativeness, clinical benefit, cost-effectiveness, and 
budget impact. Preference for the criteria was investigated by using Discrete Choice 
Experiments(DCE), Analytic Hierarchy Process (AHP), swing weighting (SWING), and 
direct point allocation (DIRECT). The survey was conducted in three hundred general 
population through face to face interview. Respondents were selected using strati-
fied random sampling by age, sex and region. The conditional logistic regression for 
DCE was conducted with STATA ver.12. Results: In the preference investigation 
using DCE, people preferentially considered disease severity (OR: 1.837, 95% CI: 1.673 
to 2.017), alternative drugs (OR: 1.556, 95% CI: 1.458 to 1.661), and size of population 
affected by disease (OR: 1.408, 95% CI: 1.285 to 1.543). According to the results by 
using AHP, respondents considered clinical benefit to be the most important, fol-
lowed by cost-effectiveness and disease severity as the main evaluation items. As 
estimated by SWING and DIRECT, clinical benefit was also evaluated as the most 
important item. There was no difference in the first to third priority evaluation 
items between SWING and DIRECT. ConClusions: The priorities derived from all 
methodologies show that clinical benefit and disease severity were more important 
than cost-effectiveness in general terms. In the situation where decision-making is 
mostly centered on cost-effectiveness, our results may be seen as the social demand 
that clinical benefit and the influence of applicable disease should be reflected 
appropriately in the insurance coverage.
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objeCtives: The aim of our study is to analyse the biosimilar bids of the Hungarian 
National Health Insurance Fund Administration in case of colony-stimulating fac-
tor (CSF) products. Methods: Data derived from the nationwide pharmaceutical 
database of Hungarian National Health Insurance Fund Administration (NHIFA). We 
analysed how the number of patients treated by colony-stimulating factor products 
changed before (01.07.2011.-30.06.2012.) and after (01.07.2012.-30.06.2014.) the first 
biosimilar bid performed in March 2012 in Hungary. Results: In the 12 months 
before biosimilar bid 27,367 patients received colony-stimulating factor treatment, 
while in the first 12 months after the bid 26,149 patients, resulting in a 4.5 % decline. 
The second 12 months after the bid 28,463 patients received colony-stimulating 
factor treatment, resulting in a 4.0 % increase. Before the biosimilar bid, the NHIFA 
spent 7.49 billion Hungarian Forint (HUF) health insurance reimbursement for CSF 
products, which decreased by 44 % to 4.19 billion HUF in the first year after bio-
similar bid. ConClusions: The analyses of the Hungarian price competition bid 
of biosimilar products showed a minimal decline in the number of patients under 
treatment by colony-stimulating factor products while the health insurance reim-
bursement of these drugs significantly decreased.
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objeCtives: To assess the ability of G-CSF (Granulocyte-Colony Stimulating Factors) 
biosimilars (G-CSF-BIOSIM) to compete with their reference (REF) within the same 
therapeutic class by analyzing EU-5 and Japanese G-CSF markets and the factors 
influencing G-CSF-BIOSIM uptakes, 3 years after a same analysis carried out in 
2011. Methods: Data on medicine volumes, values and ex-manufacturer prices for 
all G-CSF categories in the EU-5 and in Japan were provided by IMS Health. Volumes 
were calculated in DDD (Defined Daily Doses) and prices in euros per DDD. Results: 
There are two G-CSF market profiles: i) countries with a high retail market distribu-
tion (R) which are the largest G-CSF markets with low global G-CSF-BIOSIM uptakes 
(11.8% in France and 12.8% in Germany); ii) countries with a dominant hospital chan-
nel (H) which are the smallest markets with higher G-CSF-BIOSIM uptakes (56.8% in 
Spain, 40.7% in the UK and 25.2% in Italy). Japan is a special case: H market and 12.0% 
G-CSF-BIOSIM uptakes (G-CSF-BIOSIM arrived latter in Japan than in Europe). The 
G-CSF-BIOSIM uptakes depend critically on their market access at a local/regional 
level. The more the decisions are decentralized (hospitals, local purchasing structures) 
the more their uptakes are high (51.4% of the hospital market in France and 40.7% 
in the UK). The price discount between G-CSF-BIOSIM and REF plays a marginal role 
globally (-7.8% in France, and +12.2% in the UK). ConClusions: Global G-CSF-BIOSIM 
uptakes sharply increased in EU-5 countries between 2011 and 2014 (e.g. +358% in 
Spain in volume, +119% in France). We confirm the results of our first study: there 
are two G-CSF market profiles and the competition with G-CSF-BIOSIM is not mainly 
based on prices, but on local political options. The study should now be extended to 
other countries to definitively validate these results.
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Council’ (Australia, December 2005) was chosen by the working group as one of 
key prototypes of the best medical practice in lymphoma patients on evidence-
based medicine. The working group has conducted an additional search for original 
sources of scientific information in order to justify the choice of CT. The results of 
search were presented as evidence tables according to the efficacy of various CT 
regimes. In general, 56 sources have been analyzed. Results: Clinical protocols in 
lymphoma patients with taking into account the obtained data have been devel-
oped. They included medical technologies with proven efficacy. However, it should 
be noted that some of the CT schemes with sufficient efficacy in clinical trials in 
patients with recurrent and refractory forms of lymphoma, high grade of aggressive 
non-Hodgkin lymphoma include bortezomib, vinorelbine, gemcitabine, carboplatin, 
cisplatin. These agents are not licensed for lymphoma, that results in impossibility 
to prescribe such regimes to patients. ConClusions: The up-to-date CT regimes 
allow achieving better results. However, the treatment is expensive, but prolongs 
survival and improves quality of life. Thus, introduction of modern approaches 
to the treatment of lymphomas in Ukraine and harmonization of Ukrainian and 
world’s practices will provide comprehensive and effective medical care for patients.
PCN263
maPPiNg thE DiagNostiC Pathway for BrEast CaNCEr iN ENglaND aND 
ComParisoN to EuroPE
Adams EJ1, Midha D1, Postulka A2, Vecino Ortiz AI1
1Aquarius Population Health, London, UK, 2Cepheid Europe, Maurens-Scopont, France
objeCtives: Breast cancer is the most common cancer in women in England and 
the second most common cause of cancer death. In 2011, there were > 40,000 new 
breast cancer cases and > 10,000 deaths, with delay to diagnosis thought to be an 
attributing factor. Our aim was to map out the breast cancer diagnostic pathways for 
women in England, quantify the number of women proceeding through each step 
of the pathway, and compare it to the pathway in France and Germany. Methods: 
We performed literature searches for peer-reviewed papers and other published 
data from England, and conducted semi-structured interviews with cancer experts 
to understand the breast cancer diagnostic process. A patient pathway framework 
for diagnosis was modelled in Microsoft Excel and patient flow was quantified 
with published data and our own calculations where there were missing data. We 
validated the model with data from France and Germany. Results: England’s 
well-organised National Health Service Breast Screening Programme (NHSBSP) 
identifies women with early stage breast cancer to manage them promptly. Whilst 
NHSBSP coverage is 75% of invited women, only 40% of all malignancies are identi-
fied through screening, with the remaining cases from symptomatic referrals to 
breast services. We estimated that ~230,000 women present in general practice with 
breast symptoms annually and are referred to breast services, an estimated 46,000 
symptomatic women have biopsies, yielding 24,528 malignant cases. The ratio of 
women attending breast services, having a biopsy, and having a malignancy differ 
between screened and symptomatic women. The diagnostic pathway is similar in 
France and Germany, although the proportion identified through screening dif-
fers. ConClusions: Data on the full breast cancer diagnostic pathway are sparse, 
especially for women with symptoms. Our complete diagnostic pathway gives a full 
understanding about the diagnostic process, tests conducted, and quantifies the 
burden on healthcare services.
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objeCtives: Radiation oncologists and radiation therapists are key medical 
personnel involved with radiation therapy (RT). The objective was to determine 
costs associated with RT-personnel using provincial (Ontario) administrative data-
bases. Methods: A cohort of women diagnosed with primary breast cancer (BC) 
(ICD-9 174.x) was identified from the Ontario Cancer Registry (2007-2010) with up 
to one year follow-up timeframe. Radiation oncologists bill patient visits to the 
Ontario Health Insurance Plan (OHIP). Visits with $0 charge were excluded. Radiation 
therapists record planning and treatment workloads (conventional and intensity 
modulated RT or IMRT) using National Health Productivity Improvement Program 
(NHPIP) activity codes in the Activity Level Reporting (ALR) database. An hourly 
wage was then applied to these codes to determine costs within the first year 
after diagnosis. Results: We identified 30,338 women diagnosed with primary BC, 
86% (N= 26,121) of whom visited a radiation oncologist. The average cost of these 
visits per patient was $1,013 ± $607. The total number of visits was 165,060 and the 
total cost was $26.5 million. Approximately 62% of the cohort received planning 
(N= 18,859) and treatment (N= 18,758) for conventional RT by radiation therapists and 
the average cost per patient was $479 ± $326 and $282 ± $176, respectively. The total 
planning and treatment cost for conventional RT was $9.0 million and $5.3 million, 
respectively. For IMRT planning (N= 1,631) and treatment (N= 5,883), the average cost 
per patient was $158 ± $84 and $637 ± $297, respectively. The total planning and 
treatment cost for IMRT was $258,239 and $3.7 million, respectively. The overall cost 
of radiation oncologist and RT visits was $44.8 million. ConClusions: Personnel 
costs for delivering RT to breast cancer patients in the first year after their diagno-
sis are significant. Future work will be to incorporate the cost of other personnel 
involved with RT, such as medical physicists and nurses.
PCN265
mEasuriNg thE imPortaNCE of DECisioN makiNg CritEria for 
aNtiCaNCEr Drug rEimBursEmENt iN korEa
Kwon S, Park S, Lee E
College of Pharmacy, Sungkyunkwan University, Suwon, South Korea
objeCtives: The cost-effectiveness, based on economic evaluation, has been 
an important basis for reimbursement decisison making in Korea. Recently, the 
